HIV-1 Subtype C-Infected Individuals Maintaining High Viral Load as Potential Targets for the "Test-and-Treat'' Approach to Reduce HIV Transmission

被引:46
|
作者
Novitsky, Vladimir [1 ,2 ]
Wang, Rui [3 ]
Bussmann, Hermann [1 ,2 ]
Lockman, Shahin [1 ,2 ]
Baum, Marianna [4 ]
Shapiro, Roger [1 ,2 ]
Thior, Ibou [1 ,2 ]
Wester, Carolyn [1 ,2 ]
Wester, C. William [1 ,2 ,8 ]
Ogwu, Anthony [1 ,2 ]
Asmelash, Aida [1 ,2 ]
Musonda, Rosemary [1 ,2 ]
Campa, Adriana [4 ]
Moyo, Sikhulile [2 ]
van Widenfelt, Erik [2 ]
Mine, Madisa [2 ]
Moffat, Claire [1 ,2 ]
Mmalane, Mompati [2 ]
Makhema, Joseph [1 ,2 ]
Marlink, Richard [1 ,2 ]
Gilbert, Peter [5 ,6 ]
Seage, George R., III [7 ]
DeGruttola, Victor [3 ]
Essex, M. [1 ,2 ]
机构
[1] Harvard Univ, Sch Publ Hlth, AIDS Initiat, Dept Immunol & Infect Dis, Boston, MA 02115 USA
[2] Botswana Harvard AIDS Inst Partnership, Gaborone, Botswana
[3] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA
[4] Florida Int Univ, Dept Nutr & Dietet, Robert R Stempel Sch Publ Hlth, Miami, FL 33199 USA
[5] Univ Washington, Dept Biostat, Seattle, WA 98195 USA
[6] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA
[7] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA
[8] Vanderbilt Univ, Sch Med, Div Infect Dis, VIGH, Nashville, TN 37212 USA
来源
PLOS ONE | 2010年 / 5卷 / 04期
关键词
HUMAN-IMMUNODEFICIENCY-VIRUS; RANDOMIZED CLINICAL-TRIAL; ANTIRETROVIRAL THERAPY; HETEROSEXUAL TRANSMISSION; TYPE-1; INFECTION; NATURAL-HISTORY; SOUTHERN AFRICA; RISK-FACTORS; RNA LEVELS; BOTSWANA;
D O I
10.1371/journal.pone.0010148
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
The first aim of the study is to assess the distribution of HIV-1 RNA levels in subtype C infection. Among 4,348 drug-naive HIV-positive individuals participating in clinical studies in Botswana, the median baseline plasma HIV-1 RNA levels differed between the general population cohorts (4.1-4.2 log(10)) and cART-initiating cohorts (5.1-5.3 log(10)) by about one log(10). The proportion of individuals with high (>= 50,000 (4.7 log(10)) copies/ml) HIV-1 RNA levels ranged from 24%-28% in the general HIV-positive population cohorts to 65%-83% in cART-initiating cohorts. The second aim is to estimate the proportion of individuals who maintain high HIV-1 RNA levels for an extended time and the duration of this period. For this analysis, we estimate the proportion of individuals who could be identified by repeated 6- vs. 12-month-interval HIV testing, as well as the potential reduction of HIV transmission time that can be achieved by testing and ARV treating. Longitudinal analysis of 42 seroconverters revealed that 33% (95% CI: 20%-50%) of individuals maintain high HIV-1 RNA levels for at least 180 days post seroconversion (p/s) and the median duration of high viral load period was 350 ( 269; 428) days p/s. We found that it would be possible to identify all HIV-infected individuals with viral load >= 50,000 ( 4.7 log(10)) copies/ml using repeated six-month-interval HIV testing. Assuming individuals with high viral load initiate cART after being identified, the period of high transmissibility due to high viral load can potentially be reduced by 77% ( 95% CI: 71%-82%). Therefore, if HIV-infected individuals maintaining high levels of plasma HIV-1 RNA for extended period of time contribute disproportionally to HIV transmission, a modified "test-and-treat'' strategy targeting such individuals by repeated HIV testing (followed by initiation of cART) might be a useful public health strategy for mitigating the HIV epidemic in some communities.
引用
收藏
页数:10
相关论文
共 38 条
  • [31] High rate of maternal-infant transmission of hepatitis G virus in HIV-1 and hepatitis C virus-infected women
    Palomba, E
    Bairo, A
    Tovo, PA
    ACTA PAEDIATRICA, 1999, 88 (12) : 1392 - 1395
  • [32] High viremia and low level of transmitted drug resistance in anti-retroviral therapy-naive perinatally-infected children and adolescents with HIV-1 subtype C infection
    Neogi, Ujjwal
    Sahoo, Pravat Nalini
    De Costa, Ayesha
    Shet, Anita
    BMC INFECTIOUS DISEASES, 2012, 12
  • [33] Coreceptor Usage, Diversity, and Divergence in Drug-Naive and Drug-Exposed Individuals from Malawi, Infected with HIV-1 Subtype C for More Than 20 Years
    Seager, Ishla
    Travers, Simon A.
    Leeson, Michael D.
    Crampin, Amelia C.
    French, Neil
    Glynn, Judith R.
    McCormack, Grace P.
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2014, 30 (10) : 975 - 983
  • [34] Epitopes Immediately below the Base of the V3 Loop of gp120 as Targets for the Initial Autologous Neutralizing Antibody Response in Two HIV-1 Subtype B-Infected Individuals
    Tang, Haili
    Robinson, James E.
    Gnanakaran, S.
    Li, Ming
    Rosenberg, Eric S.
    Perez, Lautaro G.
    Haynes, Barton F.
    Liao, Hua-Xin
    LaBranche, Celia C.
    Korber, Bette T.
    Montefiori, David C.
    JOURNAL OF VIROLOGY, 2011, 85 (18) : 9286 - 9299
  • [35] To achieve 95-95-95 targets we must reach men and youth: High level of knowledge of HIV status, ART coverage, and viral suppression in the Botswana Combination Prevention Project through universal test and treat approach
    Lebelonyane, Refeletswe
    Bachanas, Pamela
    Block, Lisa
    Ussery, Faith
    Alwano, Mary Grace
    Marukutira, Tafireyi
    El Halabi, Shenaaz
    Roland, Michelle
    Abrams, William
    Ussery, Gene
    Miller, James A.
    Lockman, Shahin
    Gaolathe, Tendani
    Holme, Molly Pretorius
    Hader, Shannon
    Mills, Lisa A.
    Wirth, Kathleen
    Bock, Naomi
    Moore, Janet
    PLOS ONE, 2021, 16 (08):
  • [36] High Prevalence of the K65R Mutation in HIV-1 Subtype C Infected Patients Failing Tenofovir-Based First-Line Regimens in South Africa
    Skhosana, Lindiwe
    Steegen, Kim
    Bronze, Michelle
    Lukhwareni, Azwidowi
    Letsoalo, Esrom
    Papathanasopoulos, Maria A.
    Carmona, Sergio C.
    Stevens, Wendy S.
    PLOS ONE, 2015, 10 (02):
  • [37] Quadruple-2 protease inhibitors (PI)-therapy does not accelerate viral decay and suppression in PI-naive HIV-1 infected patients with severe immunosuppression and high viral load as compared with standard triple therapy
    Portilla, J
    Boix, V
    Garcia-Henarejos, JA
    Llopis, C
    Martínez-Madrid, O
    Gimeno, A
    Sánchez-Paya, J
    Merino, E
    INTERNATIONAL JOURNAL OF STD & AIDS, 2005, 16 (12) : 807 - 810
  • [38] Ledipasvir/Sofosbuvir for 8 Weeks to Treat Acute Hepatitis C Virus Infections in Men With Human Immunodeficiency Virus Infections: Sofosbuvir-Containing Regimens Without Interferon for Treatment of Acute HCV in HIV-1 Infected Individuals
    Naggie, Susanna
    Fierer, Daniel S.
    Hughes, Michael D.
    Kim, Arthur Y.
    Luetkemeyer, Annie
    Vu, Vincent
    Roa, Jhoanna
    Rwema, Steve
    Brainard, Diana M.
    McHutchison, John G.
    Peters, Marion G.
    Kiser, Jennifer J.
    Marks, Kristen M.
    Chung, Raymond T.
    CLINICAL INFECTIOUS DISEASES, 2019, 69 (03) : 514 - 522